908
Views
1
CrossRef citations to date
0
Altmetric
Editorial

How would patent reform legislation in the United States impact the pharmaceutical industry?

, JD PhD (Partner ) (Author) (Partner ) (Author)
Pages 131-133 | Published online: 12 Nov 2014
 

Abstract

The United States Congress is attempting to tackle a perceived problem with so-called ‘patent trolls’ by introducing legislation directed at the particular traits attributable to these patent holders. Two of these proposed provisions involve fee-shifting and heightened pleading standards. The problem is that these legislative proposals are not narrowly tailored, but rather are blunt instruments that will likely impact all patent holders. This threat is particularly problematic for the pharmaceutical industry, where the proposed patent reform is likely to disrupt the delicate balance established for Hatch-Waxman-type litigation.

Declaration of interest

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.